论文部分内容阅读
目的:研究TAC方案联合西黄丸对Ⅲ期乳腺癌患者P53、HER-2、TOPⅡ影响。方法:回顾性分析2014年3月至2016年2月在本院进行治疗的ⅡI期乳腺癌患者78例,根据治疗方法分为对照组和观察组。对照组患者采用TAC方案治疗,观察组患者采用TAC方案联合西黄丸治疗。评价两组患者的临床疗效、治疗前和治疗后P53基因(P53)、人表皮生长因子受体-2(HER-2)、拓扑异构酶Ⅱ(TOP-Ⅱ)表达情况,以及雌激素水平。结果:观察组总有效率显著高于对照组(P<0.05)。观察组和对照组的P53水平比较无显著性差异(P>0.05)。观察组HER-2、TOP Ⅱ阳性表达率显著低于对照组(P<0.05)。治疗后,观察组促黄体生成素(LH)、促卵泡生成素(FSH)水平显著高于对照组(P<0.05),血清雌酮(E1)、雌二醇(E2)水平显著低于对照组(P<0.05)。结论:TAC方案联合西黄丸治疗ⅡI期乳腺癌可有效改善患者雌激素水平,降低HER-2及TOPⅡ阳性表达率,值得推广应用。
Objective: To study the effect of TAC combined with Xi Huang Wan on P53, HER-2 and TOPⅡ in patients with stage Ⅲ breast cancer. Methods: A retrospective analysis of 78 patients with stage III breast cancer treated in our hospital from March 2014 to February 2016 was divided into control group and observation group according to the treatment method. Patients in the control group were treated with TAC regimen, and patients in the observation group were treated with TAC regimen in combination with Xiyhuang Pill. To evaluate the clinical efficacy, the expression of P53, HER-2 and TOP-Ⅱ, and the levels of estrogen in both groups before and after treatment . Results: The total effective rate in observation group was significantly higher than that in control group (P <0.05). P53 levels in observation group and control group showed no significant difference (P> 0.05). The positive expression rates of HER-2 and TOP Ⅱ in the observation group were significantly lower than those in the control group (P <0.05). After treatment, the levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH) in the observation group were significantly higher than those in the control group (P <0.05), and the levels of serum estrone (E2) and estradiol Group (P <0.05). Conclusion: TAC combined with Xiyhuang Pill can effectively improve the level of estrogen and reduce the expression of HER-2 and TOPⅡ in breast cancer of stage III, which is worth popularizing.